Blog Post | Focus on Regulation | 23 May 2017
Excessive pricing in pharmaceutical products attracts the European Commission’s attention
In recent years competition authorities in a number of EU Member States have stepped up in their pursuit against companies active in the Life Sciences sector for excessive pricing. Last week, the European Commission issued a press release signalling that it will not be left behind on the action when it launched a probe into a pharmaceutical supplier of cancer drugs. This could be one of the very first examples of intervention at the European Commission level in a pure excessive pricing case, let alone in the Life Sciences sector.
To read more, click here.
Download PDF Back To Listing
